|

Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis

RECRUITINGSponsored by Hoffmann-La Roche
Actively Recruiting
SponsorHoffmann-La Roche
Started2026-09-23
Est. completion2029-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions).
* Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information.
* The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation.
* Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable.

Exclusion Criteria:

* Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment.
* Prior treatment with rituximab.
* Contraindications to ocrelizumab as per the local prescribing information.
* Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes.
* Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results.
* For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.

Conditions2

Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.